RBC Capital on Pliant Therapeutics (PLRX): 'we believe there was nothing concerning emerging from the call '
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to RBC Capital on Pliant Therapeutics (PLRX): 'we believe there was nothing concerning emerging from the call '
July 11, 2022 9:47 AM EDT
Pliant Therapeutics Inc. (NASDAQ: PLRX) Halted Again on Volatility, Up 141%
...
More
July 11, 2022 9:32 AM EDT
Pliant Therapeutics Inc. (NASDAQ: PLRX) Halted on Volatility, Up 103%
...
More
July 11, 2022 9:19 AM EDT
Pre-Open Stock Movers:
La Jolla Pharmaceutical Company (Nasdaq: LJPC) 81% HIGHER; Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per... More
July 11, 2022 9:11 AM EDT
Cantor Fitzgerald analyst Pete Stavropoulos raised the price target on Pliant Therapeutics (NASDAQ: PLRX) to $36.00 (from $28.00) while maintaining a Overweight rating.... More
July 11, 2022 9:01 AM EDT
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $45.00 price target on Pliant Therapeutics (NASDAQ: PLRX).
The analyst comments "Last night, we spoke with Pliant management following yesterday's eagerly awaited release of the top-line results of its Phase 2a INTEGRIS-IPF study (NCT04396756) of lead drug PLN-74809 administered over 12 weeks in 90 patients with idiopathic pulmonary fibrosis (IPF). Importantly, across the three active dose arms (40, 80 and 160 mg) plus placebo, 80% of enrolled patients were on stable doses of standard-of-care (SoC), equally distributed between nintedanib and pirfenidone. As we expected, and consistent with prior... More
July 11, 2022 5:42 AM EDT
Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The trial met its primary and secondary endpoints demonstrating that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile. The trials exploratory efficacy endpoints assessing changes in forced vital capacity (FVC) and Quantitative Lung Fibrosis (QLF) imaging, demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks in PLN-74809 treated patients.
INTEGRIS-IPF is a randomized, double-blind,... More
